{"title":"纳曲酮治疗 OUD 的快速启动方案","authors":"Alison Knopf","doi":"10.1002/cpu30877","DOIUrl":null,"url":null,"abstract":"<p>Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"5-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rapid initiation protocol for naltrexone for OUD\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/cpu30877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.</p>\",\"PeriodicalId\":22496,\"journal\":{\"name\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"volume\":\"26 7\",\"pages\":\"5-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpu30877\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Child & Adolescent Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpu30877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
